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Given the association of mortality with elevated KSHV viral load in critically ill HIV-infected patients 
with suspected but not microbiologically confirmed tuberculosis, KSHV viral load and KICS criteria may 
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Background: Despite increasing numbers of human immunodeficiency virus (HIV)-infected South 5 
Africans receiving antiretroviral therapy (ART), tuberculosis remains the leading cause of mortality. 6 
Approximately 25% of patients treated for tuberculosis have microbiologically unconfirmed 7 
diagnoses. We assessed whether elevated Kaposi’s sarcoma-associated Herpes Virus (KSHV) viral load 8 
(VL) contributes to mortality in hospitalized HIV-infected patients investigated for tuberculosis.  9 
Methods: 682 HIV-infected patients admitted to Khayelitsha Hospital, South Africa, were recruited, 10 
investigated for tuberculosis, and followed for 12-weeks. KSHV-serostatus, peripheral blood KSHV-VL, 11 
and KSHV-associated clinical correlates were evaluated.   12 
Results: Median CD4 count was 62 cells/μL (range: 0-526); KSHV-seropositivity was 30.7% (95%CI: 27-13 
34%); 5.8% had detectable KSHV-VL (median 199.1; range: 13.4-2.2x106 copies/106 cells); 22% died. 14 
Elevated KSHV-VL was associated with mortality (adjusted OR=6.5 [95%CI: 1.3, 32.4]) in patients 15 
without tuberculosis or other microbiologically confirmed co-infections (n=159). Six patients had 16 
“possible KSHV-inflammatory cytokine syndrome (KICS)”: five died, representing significantly worse 17 
survival (p<0.0001), and one was diagnosed with KSHV-associated multicentric Castleman disease at 18 
autopsy.  19 
Conclusion: Given the association of mortality with elevated KSHV-VL in critically ill HIV-infected 20 
patients with suspected but not microbiologically confirmed tuberculosis, KSHV-VL and KICS criteria 21 
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Acquired immunodeficiency syndrome (AIDS)-related deaths have declined from an estimated 1.9 30 
million in 2005 to 1.0 million in 2016, due to global scale-up of antiretroviral therapy (ART). Of those, 31 
730,000 occurred in Sub-Saharan Africa (SSA) [1]. Although ART scale-up has led to a global shift in the 32 
proportion of deaths from communicable diseases towards chronic non-communicable conditions [2, 33 
3], in SSA, tuberculosis (TB) remains the leading cause of mortality among human immunodeficiency 34 
virus (HIV)-infected individuals, resulting in a third of all AIDS-related deaths [4, 5].  35 
The high burden of suspected TB in South Africa has led to overdiagnosis and overtreatment, and 36 
associated delay in diagnosis of cancers such as lymphoma and lung cancer given their overlapping 37 
clinical findings [6, 7]. Symptoms of Kaposi’s sarcoma-associated herpesvirus (KSHV, or human 38 
herpesvirus-8)-associated diseases may also mimic TB. KSHV is the etiological agent of Kaposi’s 39 
sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD), which 40 
primarily occur in HIV-infected patients [8-10]. KS is the commonest AIDS-related malignancy 41 
worldwide and of particular significance in SSA where KSHV-seroprevalence is elevated. KS incidence 42 
in HIV-infected individuals on ART in SSA is estimated to be 286/100,000 person years [11]. In Africa, 43 
there were an estimated 32,446 new cases and 17,659 deaths in 2018 [12]. KS often presents with 44 
cutaneous disease, but advanced visceral disease with limited or no cutaneous involvement may 45 
occur. In contrast, KSHV-MCD is a rare (although most certainly underreported [13]) B-cell 46 
lymphoproliferative disorder associated with KSHV lytic activation and interleukin-6 (IL-6) and IL-10 47 
associated inflammatory syndromes. A recently described KSHV-inflammatory cytokine syndrome 48 
(KICS) is also associated with KSHV lytic activation and similar cytokine dysregulation. KICS has only 49 
been described in two clinicopathologic series of six [14] and ten [15] HIV/KSHV co-infected patients 50 
in the US. Most also had KS, and two had PEL, and it has been proposed that KICS contributes to the 51 
inflammatory symptoms seen in some patients with severe KS or PEL [15]. KICS in the absence of a 52 





KSHV has latent and lytic phases characterized by distinct viral gene expression [16, 17]. In KS and PEL, 54 
KSHV expresses a limited number of latent phase genes [18, 19], and KS patients generally do not have 55 
elevated KSHV viral load (VL) in the blood [14, 20]. In contrast, lytically active KSHV in MCD and KICS 56 
expresses a broader range of genes that contribute to pathogenesis [8, 14]. KSHV-VL is elevated in 57 
MCD patients [14], and both MCD and KICS are characterized by overproduction of host IL-6, KSHV-58 
encoded vIL-6, and other cytokines, giving rise to inflammatory symptoms such as fever, wasting, 59 
hypoalbuminemia, cytopenia, hyponatremia and elevated C-reactive protein (CRP) [14]. Untreated 60 
KSHV-MCD and KICS have a high mortality [15]. KSHV-MCD diagnosis requires histologic confirmation, 61 
while KICS is a proposed clinical diagnosis requiring exclusion of KSHV-MCD [15] and other serious 62 
intercurrent infections. Rituximab is a highly effective therapy for KSHV-MCD, while management of 63 
KICS is directed at treating associated malignancies. A working case definition of KICS has been 64 
proposed [15] that may serve as a surveillance tool for individuals with HIV/KSHV co-infection who are 65 
at high risk of mortality.  66 
Few cases of MCD and no cases of KICS have been reported from SSA despite the high HIV/KSHV 67 
prevalence [13, 15, 21]. KS is an independent risk factor for death in HIV-infected people, and a 68 
broader range of KSHV-associated diseases with lytic syndromes may play an unrecognized role in HIV-69 
associated morbidity and mortality in SSA. We hypothesized that KSHV may contribute to clinical 70 
features and mortality in hospitalized HIV-associated TB-patients in South Africa, and/or be an 71 






Study design 74 
We conducted a retrospective analysis of an existing hospitalized HIV-associated TB cohort (n=682) in 75 
South Africa. The primary objective was to evaluate whether elevated KSHV-VL, defined as >100 76 
copies/106 cells, predicted 12-weeks mortality in the entire cohort, or in a subset who were culture-77 
negative for TB. Secondarily, we evaluated associations of KSHV-VL and serologic assays with clinical 78 
features in the cohort, as well as the use of clinical parameters that define KICS to predict mortality.  79 
Due to the retrospective nature of this study, no prospective sample size calculation was performed.   80 
 81 
Study cohort  82 
HIV-infected adults presenting with clinical syndromes compatible with pulmonary or extrapulmonary 83 
TB were recruited at Khayelitsha Hospital, Cape Town, South Africa from January 2014 to October 84 
2016 in the context of a study entitled “Defining interventions to reduce mortality in severe HIV-85 
associated tuberculosis” (UCT HREC/REF: 057/2013). Emergency room and medical ward patients 86 
were screened, eligible patients enrolled and written consent obtained. Eligible patients with a 87 
depressed level of consciousness were enrolled and followed up daily until they regained capacity to 88 
consent. If a patient died prior to providing consent, we obtained approval from UCT HREC to use the 89 
patient’s data. 90 
Clinical details, including physical exam with evaluation of skin and oral mucosa, and samples were 91 
collected at enrolment. CD4 count, HIV-VL, CRP, full blood and differential count and renal and liver 92 
function tests were performed by the National Health Laboratory Services, as well as serum 93 
cryptococcal antigen lateral flow assays (IMMY CrAG LFA). Citrate whole blood and plasma was stored 94 
at -80°C for KSHV-VL and immunology assays. The standardised TB diagnostic work-up included 95 
sputum induction if required. TB blood culture in Myco/Flytic bottles (Becton Dickinson Biosciences), 96 
sputum Xpert MTB/RIF assay, sputum TB culture, urine lipoarabinomannan (LAM) and urine Xpert 97 





performed in all patients who had not received intravenous antibiotics prior to presentation to 99 
hospital. Patients were followed for 12-weeks to ascertain vital status.  100 
 101 
Definition of patient groups  102 
Patients were grouped into four overlapping categories based on the presence or absence of 103 
microbiologically confirmed infections. Group 1 (n=675) consisted of the total patient cohort analysed; 104 
Group 2 (n=500) included all microbiologically confirmed TB-patients (Mycobacterium tuberculosis on 105 
culture or GeneXpert on any clinical sample or urine LAM-positive); Group 3 (n=175) included the 106 
remainder of the total patient cohort without microbiologically confirmed TB; Group 4 (n=159) 107 
consisted of Group 3 patients without another microbiologically confirmed infection  (e.g. bacterial 108 
blood stream infection or Cryptococcus spec.), although this group included some patients who were 109 
treated for TB despite negative microbiology. These groups are not mutually exclusive. 110 
 111 
Definition of “possible KICS”  112 
We evaluated Group 4 patients for KICS. The working case definition of KICS requires at least two 113 
clinical manifestations from at least two of three categories [15]: A. Symptoms (including fever, 114 
fatigue, oedema, cachexia, respiratory symptoms, gastrointestinal disturbance, arthralgia and 115 
myalgia, altered mental state and neuropathy); B. Laboratory abnormalities (anaemia, 116 
thrombocytopenia, hypoalbuminemia and hyponatremia); and C. Radiographic abnormalities 117 
(lymphadenopathy, splenomegaly, hepatomegaly and body cavity effusions), together with evidence 118 
of systemic inflammation (elevated CRP [>10mg/L]), evidence of KSHV lytic activity (elevated (>100 119 
copies/106 cells) KSHV-VL in peripheral blood) and exclusion of MCD. As this analysis was done 120 








KSHV and IL-6 assays 125 
KSHV assays were performed for all patients. Cryopreserved plasma was tested by ELISAs for 126 
antibodies against latency associated nuclear antigen (LANA, ORF73) and a lytic structural glycoprotein 127 
(K8.1), following established specifications [22]. Participants were considered KSHV-seropositive if 128 
antibodies to either antigen were detected [22]. Plasma IL-6 was measured using the Human IL-6 129 
SimpleStep ELISA kit (Abcam), with a minimum detectable dose of 1.6pg/mL (the reference median 130 
for IL-6 in well HIV-positive patients being 1.80pg/mL (IQR 1.20-2.89) [23]). 131 
DNA was extracted from peripheral blood mononuclear cells (PBMCs) with plasma removed using the 132 
QIAamp DNA Blood Mini kit (Qiagen). DNA concentration was adjusted to 25ng/μL, with 10μL used 133 
per PCR reaction (total volume: 50μL) to detect KSHV DNA using 100pmole K6 gene region forward 134 
and reverse primers, 5pmole FAM/TAMRA labelled probe [24] and 2X Universal Master Mix (Applied 135 
Biosystems). KSHV DNA was quantified against a K6-plasmid standard curve on a LightCycler®480II 136 
System (Roche) as follows: 2min 50°C; 8min 95°C; 45 cycles: 15sec 95°C; 1min 60°C. Cellular 137 
equivalents were determined using a quantitative assay for human endogenous retrovirus 3 (ERV-3) 138 
[25]. Samples were tested in triplicate, averaged and reported as viral DNA copies per million cells.  139 
 140 
Post-mortem histology 141 
After obtaining consent from the family, an excisional cervical lymph node biopsy was performed 2 142 
days post-mortem on a patient with possible KICS. Tissue was fixed in 10% formal saline for 48h, 143 
processed overnight in a Tissue-Tek Vacuum Infiltration Processor (Sakura Finetek) and embedded in 144 
paraffin. Tissue sections were cut at 4µm thickness and stained with haematoxylin-and-eosin and 145 
ORF73 immunoperoxidase (Cell Marque) and the Benchmark XT automated staining platform with the 146 
Ventana ultraView Universal DAB Detection kit (Roche Diagnostics). Immunostaining for kappa and 147 
lambda light chains was also performed. Photomicrographs were obtained with an Olympus SC30 3.3 148 
megapixel USB digital colour camera attached to an Olympus BX41 microscope using analySIS getIT 149 





Statistical analysis 151 
KSHV-VL was treated both as a categorical variable (elevated >100 copies/106 cells versus ≤100 152 
copies/106 cells or non-detectable) and a continuous variable and assessed for association with 153 
mortality using the Chi-square, Fisher exact, or Wilcoxon rank sum tests, as appropriate. The 154 
relationship between KSHV-VL and mortality was assessed by binomial logistic regression, controlling 155 
for age, sex, CD4 count and ART status. Linearity of the continuous variables with respect to the logit 156 
of the dependent variable was confirmed via the Box-Tidwell procedure [26] and studentized residuals 157 
with values less than 2.5 standard deviations were accepted.  158 
To compare “possible KICS” patients to the remainder of the cohort, associations of categorical 159 
variables (sex, receiving ART, KSHV-seropositivity, presence of skin KS) and continuous variables (age, 160 
weight, HIV-VL, CD4 count, KSHV-VL, K8.1 OD, ORF73 OD, IL-6, CRP, haemoglobin, white cell count, 161 
platelet count, albumin, sodium) were assessed by Fisher exact or Wilcoxon rank sum tests, 162 
respectively. To assess the independent associations of KSHV-seropositivity or KSHV-antibody levels 163 
(OD) with mortality, binomial logistic regression or multiple linear regression was performed, 164 
respectively. Continuous variables were transformed, where appropriate, to approximate normal 165 
distributions. Survival analysis was performed using Kaplan-Meier method and log-rank sum test. P-166 
values are two-tailed and considered significant if <0.05. Statistical testing was performed using SPSS 167 
version 25 (IBM Corp, 2017). Performance characteristics of KICS criteria for predicting death were 168 






Assessment of clinical parameters  171 
Of all the patients recruited (n=682), 7 were excluded (2 withdrew, 1 was HIV-negative, 4 had no blood 172 
samples stored). 675 are included in this analysis. 12/675 (1.8%) were lost to follow-up, and 146/675 173 
(22%) were confirmed dead by 12-weeks follow-up. Median CD4 count was 62 cells/μL (range: 0-526 174 
cells/μL) (Table 1). 10 patients had a clinical diagnosis of cutaneous or oral KS at enrolment (4 in Group 175 
2, 6 in Group 3, of which 5 were in Group 4). 207/675 patients (30.7%, 95%CI: 27-34%) were KSHV-176 
seropositive, of whom 39 (5.8%) showed detectable VL in the blood (median 199.1; range: 13.4-177 
2.2x106 copies/106 cells) (Table 1). Plasma IL-6 was detected in 559 (82.8%) of all patients with a 178 
median concentration of 42.3pg/mL (IQR: 9.8-103.8pg/mL), being highly elevated compared to a 179 
reference population of HIV-positive patients [23]. In binomial logistic regression including age, sex, 180 
CD4 count, haemoglobin levels and ART status, only CD4 count was significantly associated with KSHV-181 
seropositivity (p=0.001, adjusted OR=1.2 (95%CI: 1.1, 1.3), Supplementary Table 1A) whereas sex 182 
(male) was associated with elevated KSHV-VL (p=0.029, adjusted OR=2.4 (95%CI: 1.1, 5.1, 183 
Supplementary Table 1B) and defaulted ART status was associated with lower KSHV-VL (p=0.042, 184 
adjusted OR=0.3 (95%CI: 0.1, 1.0, Supplementary Table 1B). Anaemia was associated with higher K8.1 185 
antibody levels (p=0.022, unstandardized coefficient=-0.033) when adjusted for age, sex, CD4 count 186 
and ART status, but not with anti-ORF73 titers (Supplementary Table 2).  187 
 188 
Elevated KSHV-VL is associated with mortality in microbiologically unconfirmed TB-patients  189 
Group 1 (n=675) was assessed for an association between elevated KSHV-VL (i.e. >100 copies/106 cells) 190 
and 12-weeks mortality. We identified 33 patients with elevated KSHV-VL of whom 9 (27.3%) died 191 
before 12-weeks, compared to 137 (21.7%) of 630 patients with VL ≤100 copies/106 cells. This 192 
difference was not statistically significant (Table 2A, Figure 1). Proven TB-patients (n=500, Group 2) 193 
also showed no significant association of KSHV-VL with mortality (Table 2A, Figure 1). However, in 194 





co-infections (n=159, Group 4), elevated KSHV-VL was detected at a higher frequency (p=0.011, 196 
OR=7.1, 95%CI: 1.6, 31.7, Table 2A). Importantly, KSHV-VL was significantly higher in patients who died 197 
than those who survived 12-weeks (p=0.0094, Figure 1), and overall 5/8 (62.5%) of Group 4 patients 198 
with elevated KSHV-VL died, compared to 28/148 (18.9%) with low or non-detectable KSHV-VL. 199 
Binomial logistic regression revealed a statistically significant association of age, CD4 count and 200 
elevated KSHV-VL with death among Group 4 patients (Table 2B). The adjusted OR for death given 201 
elevated KSHV-VL was 6.5 (95%CI: 1.3, 32.4). No significant relationship between KSHV-seropositivity 202 
and mortality was noted (data not shown).  203 
 204 
Identification and contribution of possible KICS to mortality 205 
We next evaluated Group 4 for KICS since TB and other microbiologically proven infections as alternate 206 
cause of clinical presentation had already been excluded in this group as per KICS definition [15]. We 207 
identified 6 “possible KICS” patients with the caveat of not excluding MCD at clinical presentation 208 
(Figure 2A). Compared to others in Group 4, “possible KICS” subjects were older (Table 3A), had lower 209 
platelet counts (Table 3B, Figure 2B), higher K8.1 and ORF73 antibody levels (Table 3B) and, by 210 
definition, elevated KSHV-VL (Table 3B, Figure 2B). HIV-VL and CD4 counts did not differ significantly 211 
between “possible KICS” and the remainder of Group 4 patients (Table 3A); neither did IL-6 and CRP 212 
although being markedly elevated (Table 3B, Figure 2B), nor did haemoglobin and albumin levels 213 
although being abnormally low [15] (Table 3B, Figure 2B). 214 
Finally, 12-weeks mortality among “possible KICS” patients was 83% (5/6) and thereby significantly 215 
higher compared to 18% for the remainder of the Group 4 patients. Median time to death in “possible 216 
KICS” patients was 11 days (95%CI: 0, 51) (Figure 2C), supporting previous reports of markedly 217 
elevated risk of death in KICS subjects [15]. KICS criteria identified all patients with elevated KSHV-VL 218 
in Group 4 (Table 2A) who died within 12-weeks. Moreover, KICS criteria were found to be specific for 219 
predicting death in this cohort, with the following characteristics (95%CI): sensitivity 0.15, specificity 220 





Post-hoc description of the identified “possible KICS” patients 222 
Of the six “possible KICS” patients, one was diagnosed with KSHV-associated MCD at autopsy. This 223 
patient displayed the highest KSHV-VL of the entire cohort (2,165,642 copies/106 cells) and was 224 
positive for K8.1 but not ORF73, suggesting a highly lytically active KSHV-infection. In the absence of 225 
any clinical measure of KICS or KSHV on presentation, this patient was empirically treated for TB for 226 
six months with no improvement prior to admission. He presented with further deterioration after 227 
completion of TB-treatment and died on the day of enrolment. His CD4 count was 328 cells/μL, and 228 
HIV-VL was undetectable. The patient had evidence of systemic inflammation (CRP=304mg/L) and 229 
cytokine activation (IL-6=3307pg/mL), as well as severe anaemia (haemoglobin=6.9g/dL), 230 
thrombocytopenia (platelet count=124(x103/μL)), hypoalbuminemia (albumin=16g/L), hyponatremia 231 
(sodium=125mEq/L), lymphadenopathy and hepatomegaly. KICS-associated symptoms included 232 
respiratory symptoms (cough), weight loss, nausea, body pain and weakness. Histologic examination 233 
of lymph nodes was consistent with KSHV-associated MCD (Figure 2D). There was no evidence of PEL. 234 
Two other “possible KICS” patients’ deaths were retrospectively likely attributable to KICS in the 235 
setting of KS [15]. One had biopsy-confirmed KS, was re-started on ART but died before assessment 236 
for chemotherapy. One patient, after deterioration on empiric anti-tuberculosis therapy, had skin KS 237 
confirmed on biopsy and features of lung KS on computed tomography scan 2 weeks prior to death. 238 
The other “possible KICS” patients did not have identified KSHV-associated malignancies despite 239 
elevated VL assessed retrospectively. One was started on TB-treatment empirically, deteriorated on 240 
treatment and was diagnosed with an invasive keratinizing moderately differentiated squamous cell 241 
carcinoma during evaluation of an upper gastrointestinal bleed. The other patient suffered from 242 
chronic renal failure due to urethral stricture and was admitted with an episode of acute kidney injury. 243 
The patient was treated for suspected bacterial sepsis but died within the study period. The sixth 244 






South Africa has one of the highest global rates of both HIV and TB [27]. Improved diagnostics for 247 
treatable diseases that mimic TB are needed to limit unnecessary empiric TB-treatment. Utilizing a 248 
large well characterized patient cohort presenting to a Cape Town hospital with suspected TB, we 249 
retrospectively evaluated KSHV as a contributor to mortality.   250 
KSHV-seroprevalence is high in SSA with variable regional prevalence [28]. We found 30.7% (95%CI: 251 
27-34%) KSHV-seroprevalence in Cape Town, which is in agreement with other South African 252 
estimates of 30-40% from Soweto, Johannesburg and Kwa-Zulu Natal. Of KSHV-seropositive patients, 253 
18.8% (5.8% of the entire cohort) showed detectable virus in the blood, suggestive of poor immune 254 
control of KSHV [29].    255 
Focusing on the 33 (5%) patients with elevated (>100 copies/106 cells) KSHV-VL, we found no higher 256 
mortality within the context of either the entire patient cohort or the cohort with confirmed TB, 257 
suggesting that KSHV does not play a significant role in potentiating TB mortality. However, in patients 258 
with neither microbiologically proven TB nor alternative co-infection, elevated PBMC-associated 259 
KSHV-VL was associated with 6.5 higher odds of mortality when adjusted for age, sex, CD4 count and 260 
ART status. In contrast, KSHV-seropositivity alone was not associated with mortality (data not shown), 261 
suggesting that it is the burden of KSHV that contributes to the observed association [8, 14]. Similarly, 262 
elevated plasma KSHV-VL, a marker of circulating tumour DNA, has been noted as a risk factor for 263 
death in people with established KS [30]. Although a strong association between elevated KSHV-VL 264 
and mortality among microbiologically unconfirmed TB-patients was identified, additional factors such 265 
as KSHV-associated malignancies, functional immune dysregulation (cytokine syndromes) or other 266 
pathological processes (e.g. co-infections or other cancers) likely also contribute to death. 267 
We further investigated whether application of KICS criteria [15] identified patients with a high 268 
mortality and found six “possible KICS” patients, of whom five died, with a median survival of 11 days. 269 
Three had identified untreated KSHV-associated malignancies. Although “possible KICS” patients had 270 





other critical illnesses. This suggests that CRP is a less useful screening tool than KSHV-VL in this 272 
population.  273 
To our knowledge, this is the first systematic evaluation of KICS in South Africa and has implications 274 
for other countries with high prevalence of HIV/KSHV co-infection. A study from Uganda reports that 275 
three in every ten patients with HIV-associated lymphoma had a possible misdiagnosis and were 276 
treated for TB before a final diagnosis of lymphoma was made, and our data suggest that KSHV-277 
associated diseases are important to include in the differential diagnosis of suspected TB [6].  278 
A limitation of our study was that only one of the six “possible KICS” patients had a pathological 279 
examination of a lymph node biopsy. This was performed following death and demonstrated KSHV-280 
MCD. Another had possible pulmonary KS diagnosed based on chest X-ray and confirmed cutaneous 281 
KS. It is possible that the other patients also had undiagnosed KSHV-associated diseases such as KS or 282 
MCD.  Although we have not definitively established that “possible KICS” patients died of KSHV-283 
associated malignancies in most cases, our study demonstrates that elevated KSHV-VL in the 284 
peripheral blood represents a significant parameter associated with mortality. Our data support that 285 
patients meeting KICS criteria should be evaluated for KSHV-MCD, visceral KS, or PEL, particularly in 286 
settings with oncology capacity to manage these treatable KSHV-associated malignancies. 287 
Another important finding was that the majority of the entire patient cohort was anaemic, which was 288 
significantly associated with elevated antibody levels to the KSHV lytic antigen K8.1 in KSHV-289 
seropositive Group 4 patients. This is consistent with results from a recent study from Uganda, which 290 
reported a link between elevated KSHV-serumpositivity and anaemia in the setting of malaria. 291 
Additional studies are required to evaluate this association. For example, anaemia may lead to 292 
reactivation of KSHV through relative tissue hypoxia [31], or KSHV reactivation may lead to anaemia 293 
or chronic inflammation mediated through IL-6. 294 
In sum, our data suggest that elevated KSHV-VL should be considered as an important pathology in 295 
HIV-infected patients investigated for TB, and that for those meeting other KICS criteria evaluation for 296 





facilitate more rapid TB diagnostic work-up, thereby facilitating selection of patients for whom KSHV-298 
testing may be indicated.  In selected patients, KSHV-VL has a strong prognostic value. KSHV-VL has 299 
been linked to an increased risk of KSHV-associated malignancies [32]; therefore, HIV-positive patients 300 
with elevated KSHV-VL should be evaluated for KSHV-related malignancies and treated appropriately. 301 
KSHV-associated malignancies are treatable, and earlier diagnosis may improve survival. Given its high 302 
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Figure Legends 409 
 410 
Figure 1: 12-weeks mortality versus KSHV viral load in the entire patient cohort (Group 1, n=675); 411 
patients with proven TB (Group 2, n=500); patients without proven TB (Group 3, n=175); patients 412 
without microbiologically proven co-infections (Group 4, n=159). 12 patients of the total cohort were 413 
lost to follow-up. P value is by Wilcoxon rank sum test, assessing the association of the level of KSHV-414 
VL (continuous variable) with mortality of patients with confirmed vital status at the end of the 12-415 
weeks study period. Data are log transformed. The dotted line indicates “elevated KSHV viral load” 416 
>100 copies/106 cells, and the solid lines indicate the median.  417 
 418 
Figure 2: Identification and contribution of possible KICS to mortality in a cohort of critically ill 419 
patients investigated for TB. A) Schematic flow chart showing the diagnosis of “possible KICS” by 420 
exclusion in the entire cohort. Patients were excluded if they had microbiologically proven TB or other 421 
bacterial or fungal infections and those who remained were further evaluated according to the criteria 422 
previously described in the KICS working case definition [15]. 2 patients were excluded on the basis of 423 
alternative diagnoses: TB meningitis and community-acquired pneumonia, respectively. As this 424 
analysis was done retrospectively, MCD could not be excluded at clinical presentation, hence the 425 
designation, “possible KICS” patients. B) Selected KICS-defining parameters (KSHV viral load, IL-6 level, 426 
CRP level, platelet count, albumin, haemoglobin) in “possible KICS” patients (n=6) compared to the 427 
remainder of Group 4 patients (n=153). The dotted lines mark abnormal levels (KSHV-VL>100 428 
copies/106 cells; IL-6>1.8pg/mL [23]; CRP>10mg/L, platelet count<186(x103/µL), albumin<35g/L and 429 
haemoglobin<12g/dL), and the solid lines indicate the median. P values are by Wilcoxon rank sum test. 430 
Data are log transformed where necessary. C) Overall confirmed survival at end of the 12-weeks study 431 
period in “possible KICS” patients (n=6) compared to the remainder of Group 4 patients (n=153, 432 
including 3 patients who were lost to follow-up). P value is by log-rank test. D) Histopathological 433 





KSHV-VL of the entire patient cohort. Top panel, from left to right: haematoxylin and eosin stain 435 
showing a regressed germinal center with sheets of plasma cells in the mantle zone among prominent 436 
capillaries, (20x objective magnification); haematoxylin and eosin stain showing an infiltrate of 437 
numerous benign plasma cells (40x objective magnification); immunohistochemical stain of KSHV-438 
ORF73 showing aggregates of KSHV-positive cells in the lymph node staining brown (10x objective 439 
magnification). Bottom panel, from left to right: immunohistochemical stain showing brown granular 440 
nuclear KSHV-ORF73 positivity among the numerous background plasma cells (40x objective 441 
magnification); immunohistochemistry for kappa light chains demonstrate few of the plasma cells in 442 
an area of ORF73-positive cells are kappa restricted (40x objective magnification); 443 
immunohistochemistry of lambda light chains in the area of ORF73-positive cells demonstrate a large 444 
number of the plasma cells are lambda restricted cells (40x objective magnification).   445 
 
 
 
 
 
 
 
 
 
 
 
